EU orphan status for arGentis' ARG201

23 February 2009

Tennessee, USA-based arGentis Pharmaceuticals says that the European Medicines Agency (EMEA) has accepted its product candidate ARG201  (native type 1 bovine collagen) for the treatment of diffuse systemic  sclerosis, also known as systemic scleroderma (SSc) for designation as  an orphan medicinal product in the European Union.

"With this designation our subsidiary arGentis Autoimmune Europe gains  access to incentives including 10 years marketing exclusivity throughout  Europe for the therapeutic indication for which it was granted,  facilitated access to the centralized procedure for the application for  marketing approval, reduced fees associated with applying for marketing  approval and protocol assistance, and access to EU research funding  grants," stated Ted Townsend, vice president, business development of  arGentis.

ARG201, pioneered by Arnold Postlethwaite, director of the Division of  Connected Tissue Disease at the University of Tennessee Health Science  Center, and Andrew Kang, professor of medicine in rheumatology at the  University's Health Science Center, is an immunotherapy that induces  low-dose oral immune tolerance in SSc patients causing down-regulation  of the body's autoimmune response. It has completed a Phase II clinical  trial.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight